Communiqués Sarepta Therapeutics, Inc.

Actions

SRPT

US8036071004

Produits pharmaceutiques

Temps réel estimé Cboe BZX 21:03:39 08/10/2026			Varia. 5j.	Varia. 1 janv.
17,96 ^USD	+2,60%		+2,76%	-16,10%

14:17	Sarepta Therapeutics, Inc. : RBC Capital Markets maintient son opinion neutre	ZM
30/09	Sarepta Therapeutics, Inc. présente de nouvelles données démontrant la sécurité et un bénéfice fonctionnel cliniquement significatif d’ELEVIDYS chez des patients ambulatoires plus âgés atteints de la maladie de Duchenne	CI

Communiqués

05/10	Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT	BU
30/09	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/09	Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne	BU
25/09	Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress	BU
24/09	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting	BU
08/09	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year	BU
31/08	Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	BU
24/08	Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT	BU
05/08	Sarepta Therapeutics: Q2 Earnings Snapshot	AQ
05/08	Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments	BU
30/07	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
29/07	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
27/07	Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer	BU
22/07	Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results	BU
01/07	Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45(R) and VYONDYS 53(R)	AQ
30/06	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
30/06	Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®	BU
01/06	Sarepta Therapeutics to Participate in Upcoming Investor Conferences	BU
13/05	Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	BU
07/05	Sarepta Therapeutics : 1Q 2026 Earnings Results Presentation	PU
06/05	Sarepta Therapeutics: Q1 Earnings Snapshot	AQ
06/05	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments	BU
22/04	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results	BU
31/03	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
25/03	Sarepta Therapeutics : Preliminary Phase 1 2 Clinical Data Readout for DM1 and FSHD Programs	PU